Nationwide cohort for renal cell carcinoma data collection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

PRO-RCC is a multicenter cohort study aimed at collecting real-world clinical data and patient-reported outcomes for patients with localized or metastatic renal cell carcinoma in the Netherlands. The study integrates clinical data collection with the Netherlands Cancer Registry and includes patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs). Participants can also consent to be part of 'Trial within cohorts' (TwiC) studies, allowing for randomized interventional research within the cohort framework. This infrastructure supports both observational and interventional studies to improve understanding and treatment of renal cell carcinoma.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* newly diagnosed patients with RCC or synchronous metastatic RCC
* metachronous metastasized RCC
* age \>18 years
* capable of understanding Dutch language

Exclusion Criteria:

* n/a

Where it's running

• Amsterdam UMC locatie VUMC
  Amsterdam, North Holland, Netherlands Recruiting
• Jeroen Bosch Ziekenhuis
  's-Hertogenbosch, Netherlands Recruiting
• Jeroen Bosch Ziekenhuis
  's-Hertogenbosch, Netherlands Recruiting
• Meander Medisch Centrum
  Amersfoort, Netherlands Recruiting
• Gelre ziekenhuis
  Apeldoorn, Netherlands Recruiting
• Rijnstate
  Arnhem, Netherlands Recruiting

Study contacts

• Principal investigator: Adriaan Bins, MD, PhD — Amsterdam UMC
• Study coordinator: Hilin Yildirim, MD
• Email: h.yildirim@iknl.nl
• Phone: 0031643202583

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using a digital tool to improve kidney surgery planning

  This study is testing a new digital tool to see if it helps doctors plan kidney surgery better for patients with localized kidney cancer compared to just using regular CT scans.

  Recruiting at 5 sites University Hospital, Ghent · Aalst and 4 other locations · NCT06536439

• Combining Pembrolizumab and Axitinib for Kidney Cancer with Tumor Thrombus

  This study is testing whether combining two medications, Pembrolizumab and Axitinib, can help shrink kidney cancer tumors that have spread to a major vein before surgery.

  Recruiting at 3 sites Phase 2 University of Colorado, Denver · Aurora, Colorado and 2 other locations · NCT05969496

• Plasma DNA Methylation to Classify Kidney Masses Before Surgery

  This study tests a blood-based DNA methylation test to help distinguish malignant kidney cancers from benign kidney masses in adults who are planned for kidney surgery.

  Recruiting RenJi Hospital · Shanghai, Shanghai Municipality · NCT07874542

• Your Kidney Cancer Immunotherapy: How You Get It and If Labs Can Be At Home

  This study tests whether people with kidney cancer prefer intravenous or subcutaneous immunotherapy and whether at‑home lab draws plus telehealth visits before treatment are practical.

  Recruiting at 7 sites Phase 4 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07872553

• Intensified monitoring to personalize cabozantinib dosing in advanced kidney cancer

  We will test whether closer pharmacology-based monitoring helps people with advanced kidney cancer tolerate cabozantinib better while keeping its effect against the cancer.

  Recruiting Centro di Riferimento Oncologico - Aviano · Aviano, Pordenone · NCT07805122

• Irreversible Electroporation for Recurrent Pelvic Tumors

  This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT07782164

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.